Antiviral Agents (Record no. 34070)

MARC details
000 -LEADER
fixed length control field 02429nam a2200121Ia 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 220620s9999||||xx |||||||||||||| ||und||
245 #0 - TITLE STATEMENT
Title Antiviral Agents
546 ## - LANGUAGE NOTE
Language note English[eng]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Zika virus||nucleoside analogues||antiviral agents||NS5||prodrugs||ProTides||neural stem cells||RNA-dependent RNA polymerase||cytomegalovirus||latent infection||TALEN||Surveyor nuclease mutation detection assay||ie-1 gene||quantitative real-time PCR||Epstein–Barr virus||herpes viruses||lytic gene expression||Burkitt lymphoma cells||clozapine||antipsychotic drug||antiviral drug||enteroviruses||coxsackievirus B4||persistent infection||fluoxetine||resistance||mutations||herpes B virus||macacine herpesvirus-1||genistein||flavonoids||acyclovir||ganciclovir||Plantago asiatica||Clerodendrum trichotomum||RSV||therapeutic effects||acteoside||human antimicrobial peptides||antiviral strategies||defensins||cathelicidins||hepcidins||transferrins||influenza A virus||brevilin A||antiviral||sesquiterpene lactone||replication||PRRSV||polyethylenimine||PEI||virion internalization||endocytosis||HIV||pediatrics||Ethiopia||pre-treatment drug resistance||combination antiretroviral therapy (cART)||dried plasma spots||dried blood spots||sphingolipids||glycosphingolipids||viruses||lipid biosynthesis||flavivirus||Japanese encephalitis virus||furin inhibitor||precursor membrane protein||measles virus||central nervous system||tropism||treatments||porcine reproductive and respiratory syndrome virus||ginsenoside Rg1||antiviral activity||pro-inflammatory factor||NF-κB signaling pathway||acute/latent infection||congenital infection||antiviral agent||therapeutic strategies||nucleic acid-based therapeutic approach||HCMV vaccine||adoptive cell therapy||Rev response element||chemical footprinting||SHAPE||drug discovery||branched peptides||herpesvirus||immediate-early||IE1||IE2||ribozyme||RNA interference||CRISPR/Cas||small molecule||orthohantavirus||phenyl-benzotriazoles||C-FRA||Porcine circovirus type 2||epigallocatechin gallate||heparan sulfate||antiviral effect||virus attachment||microvirin||lectin||human immunodeficiency virus||hepatitis C virus||antiviral inhibitor||non-immunogenic||viral entry||protein drugs||LUMS1||oleanane-type derivatives||influenza A virus (IAV)||virus entry inhibitors||hemagglutinin (HA)||n/a
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Adamson, Catherine
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://mdpi.com/books/pdfview/book/2737">https://mdpi.com/books/pdfview/book/2737</a>
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type E-Books
Holdings
Withdrawn status Lost status Damaged status Not for loan Home library Current library Date acquired Total Checkouts Date last seen Price effective from Koha item type
        Kerala University of Digital Sciences, Innovation and Technology Knowledge Centre Kerala University of Digital Sciences, Innovation and Technology Knowledge Centre 20/06/2022   20/06/2022 20/06/2022 E-Books